Announced entry into an agreement to be acquired by XOMA Royalty Corporation for between $1.16 and $1.24 per share in cash, ...

XOMA Royalty adds milestone and royalty economics associated with two partnered assetsEMERYVILLE, Calif. and UTRECHT, The ...

The royalty aggregator’s proposed deals for HilleVax and Lava add to a pattern of “zombie” biotech buyouts this year as the ...

EMERYVILLE, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, reported its 2025 second quarter and year to date financial results and ...

Explore XOMA's shift to M&A with CVRs, recent LVTX & HLVX deals, and their potential impact. Learn why analysts maintain a ...

Key Points Revenue (GAAP) beat estimates by 39.5% in Q2 2025, rising to $13.1 million on substantial milestone receipts. Recurring royalty income remained modest, with only $2.6 million from ...

LAVA Therapeutics N.V. (NASDAQ:LVTX) saw its stock rise 4.2% following news of a share purchase agreement with XOMA Royalty ...

XOMA Royalty Corporation (NASDAQ:XOMA) has unveiled plans to acquire two biotech firms—HilleVax, Inc. (NASDAQ:HLVX) and LAVA ...

Xoma Royalty has agreed to acquire Lava Therapeutics.

The firm will continue developing Lava's two partnered bispecific gamma delta T-cell engager programs with Pfizer and Johnson & Johnson.

In a separate transaction, XOMA Royalty will acquire LAVA Therapeutics for between $1.16 and $1.24 per share in cash, plus a CVR representing the right to receive 75% of net proceeds related to LAVA’s ...

Under the terms of the agreement, XOMA Royalty will acquire LAVA for between $1.16 and $1.24 per share in cash, plus a non-transferable contingent value right (CVR) representing 75% of net proceeds ...